
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
An in-depth review on Homologous Recombination Deficiency (HRD) and PARP inhibitor maintenance (Olaparib, Niraparib) in ovarian and pancreatic cancers, synthetic lethality mechanisms, and hematologic toxicity management.
CRITICAL CLINICAL RED FLAG: Persistent macroscopic cytopenias (Hb <8 g/dL, Platelets <50,000/mcL, ANC <1000/mcL) lasting >4-6 weeks despite PARP inhibitor dose reductions warrant bone marrow aspiration and cytogenetic workup to rule out Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML).
Normal cells utilize two distinct DNA repair mechanisms: Poly(ADP-ribose) Polymerase (PARP) enzymes repair single-strand DNA breaks via Base Excision Repair (BER), whereas BRCA1/BRCA2 and the Homologous Recombination (HR) pathway repair catastrophic double-strand breaks. In tumor cells harboring germline/somatic BRCA mutations or Homologous Recombination Deficiency (HRD), pharmacological PARP inhibition (Olaparib, Niraparib, Rucaparib) traps PARP at DNA replication forks, converting single-strand lesions into unrepairable double-strand breaks that trigger selective cancer cell apoptosis—a biological mechanism termed "Synthetic Lethality."
Advanced High-Grade Serous Ovarian Cancer (SOLO-1 Trial): First-line maintenance Olaparib in BRCA-mutated advanced ovarian cancer demonstrates a median progression-free survival of 56.0 months versus 13.8 months for placebo, achieving unprecedented 5-year remission rates.
Metastatic Pancreatic Adenocarcinoma (POLO Trial): Maintenance Olaparib in germline BRCA-mutated pancreatic cancer whose disease had not progressed during frontline platinum-based chemotherapy nearly doubled progression-free survival (7.4 vs. 3.8 months).
Genomic Scar Testing / Genomic Instability Score (GIS) evaluates Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST). Patients with HRD-positive tumors (GIS score >=42 or Myriad myChoice HRD positive) without BRCA mutations derive substantial clinical benefit from PARP inhibitor maintenance combined with Bevacizumab (PAOLA-1 regimen).
"Synthetic lethality with PARP inhibitors has transformed advanced ovarian and pancreatic cancer maintenance, converting platinum sensitivity into durable, years-long remission." — Dr. Neha Gupta
Baseline complete blood counts (CBC) must be monitored weekly for the first month, bi-weekly for the next 2 months, and monthly thereafter. For Grade 3/4 anemia or thrombocytopenia, interrupt treatment until recovery to <=Grade 1, then resume with structured dose decrements (e.g., Olaparib 300 mg BID reduced to 250 mg BID; Niraparib individualized baseline dosing based on weight <77 kg or platelets <150,000/mcL).
1. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO-1). New England Journal of Medicine (NEJM), 2018; 379: 2495-2505.
2. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (POLO Trial). NEJM, 2019; 381: 317-327.
3. Ray-Coquard I, Pautier P, Colonval S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1/ENGOT-ov25). NEJM, 2019; 381: 2416-2428.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.